Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT43AI)

Drug Name
SIB-1508Y Drug Info
Synonyms
CHEMBL111580; 3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine; 179120-51-5; 5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine; 5-Ethynyl Nicotine; 179120-92-4; 3-ethynyl-5-(1-methyl-2-pyrrolidinyl)pyridine; AC1L326X; SCHEMBL1155706; BDBM86544; NUPUDYKEEJNZRG-UHFFFAOYSA-N; CHEBI:125396; NSC_6442277; CAS_192231-16-6; 3-ethynyl-5-(1-methylpyrrolidin-2-yl)-pyridine; 3-(1-Methylpyrrolidine-2-yl)-5-ethynylpyridine; A812432
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Terminated [1]
Cross-matching ID
PubChem CID
3036156
CAS Number
CAS 179120-92-4
TTD Drug ID
DMT43AI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Varenicline DMMUOLJ Drug dependence Approved [3]
Metocurine Iodide DMZJYBW Anaesthesia 9A78.6 Approved [4]
AZD-1446 DM7B1AR Alzheimer disease 8A20 Phase 2 [5]
TC-6499-12 DMWPI2U Irritable bowel syndrome DD91.0 Phase 2 [6]
Sofinicline DM157U0 Attention deficit hyperactivity disorder 6A05.Z Phase 2 [7]
CP-601927 DMKJFDM Gastrointestinal disease DE2Z Phase 2 [8]
TC-2216 DM4W92J Mood disorder 6A60-6E23 Phase 1 [9]
SUVN 911 DMZP671 Major depressive disorder 6A70.3 Phase 1 [10]
Dianicline DMX2SHT Tobacco dependence 6C4A.2 Discontinued in Phase 3 [11]
TC-2696 DMP1A4S Pain MG30-MG3Z Discontinued in Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) TTL1ATN ACHA4_HUMAN; ACHB2_HUMAN Modulator [2]

References

1 Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist. Brain Res. 2008 Oct 9;1234:16-24.
2 Nicotinic Receptors in Neurodegeneration
3 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
4 NMR study of general anesthetic interaction with nAChR beta2 subunit.Biophys J.2008 Mar 1;94(5):1681-8.
5 A randomized, double-blind, placebo-controlled crossover study of 4 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder.Psychopharmacology (Berl). 2014 Mar;231(6):1251-65.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2014 Aug;23(8):1157-63.
8 Toxicity study in juvenile rats with the alpha4beta2 nicotinic acetylcholine receptor partial agonist CP-601,927. Birth Defects Res B Dev Reprod Toxicol. 2011 Aug;92(4):323-32.
9 TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity.CNS Neurosci Ther.2008 Winter;14(4):266-77.
10 Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine alpha42 Receptor Antagonist for the Treatment of Depression. J Med Chem. 2020 Mar 26;63(6):2833-2853.
11 Dianicline, a novel 42 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial.Nicotine Tob Res.2011 Jan;13(1):1-6.
12 alpha4beta2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology. 2013 Aug;71:191-203.